Deisseroth A - Search Results

1

Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.

Tang Y, Akbulut H, Maynard J, Petersen L, Fang X, Zhang WW, Xia X, Koziol J, Linton PJ, Deisseroth A. Tang Y, et al. Among authors: deisseroth a. J Immunol. 2006 Oct 15;177(8):5697-707. doi: 10.4049/jimmunol.177.8.5697. J Immunol. 2006. PMID: 17015759

2

An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.

Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. Zhang L, et al. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15101-6. doi: 10.1073/pnas.2135379100. Epub 2003 Nov 25. Proc Natl Acad Sci U S A. 2003. PMID: 14645711 Free PMC article.

3

Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.

Tang Y, Zhang L, Yuan J, Akbulut H, Maynard J, Linton PJ, Deisseroth A. Tang Y, et al. Among authors: deisseroth a. Blood. 2004 Nov 1;104(9):2704-13. doi: 10.1182/blood-2003-12-4319. Epub 2004 Jul 6. Blood. 2004. PMID: 15238426 Free article.

4

Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.

Akbulut H, Tang Y, Akbulut KG, Maynard J, Zhang L, Deisseroth A. Akbulut H, et al. Among authors: deisseroth a. Mol Cancer Ther. 2006 Aug;5(8):1975-85. doi: 10.1158/1535-7163.MCT-06-0049. Mol Cancer Ther. 2006. PMID: 16928818

5

Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors.

Han TH, Tang Y, Park YH, Maynard J, Li P, Akbulut H, Petersen L, Deisseroth A. Han TH, et al. Among authors: deisseroth a. Bone Marrow Transplant. 2010 Mar;45(3):550-7. doi: 10.1038/bmt.2009.185. Epub 2009 Aug 3. Bone Marrow Transplant. 2010. PMID: 19648971

6

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.

Tang YC, Thoman M, Linton PJ, Deisseroth A. Tang YC, et al. Among authors: deisseroth a. Cancer Immunol Immunother. 2009 Dec;58(12):1949-57. doi: 10.1007/s00262-009-0718-3. Epub 2009 May 15. Cancer Immunol Immunother. 2009. PMID: 19444444 Free PMC article. Review.

7

Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.

Akbulut H, Tang Y, Maynard J, Zhang L, Pizzorno G, Deisseroth A. Akbulut H, et al. Among authors: deisseroth a. Clin Cancer Res. 2004 Nov 15;10(22):7738-46. doi: 10.1158/1078-0432.CCR-04-0490. Clin Cancer Res. 2004. PMID: 15570008

8

Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma.

Li P, Liu Y, Maynard J, Tang Y, Deisseroth A. Li P, et al. Among authors: deisseroth a. Mol Ther. 2010 May;18(5):921-8. doi: 10.1038/mt.2010.5. Epub 2010 Feb 23. Mol Ther. 2010. PMID: 20179680 Free PMC article.

9

Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells.

Akbulut H, Tang Y, Akbulut KG, Maynard J, Deisseroth A. Akbulut H, et al. Among authors: deisseroth a. Gene Ther. 2010 Nov;17(11):1333-40. doi: 10.1038/gt.2010.93. Epub 2010 Jul 1. Gene Ther. 2010. PMID: 20596057

10

TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases.

Deisseroth A, Tang Y, Zhang L, Akbulut H, Habib N. Deisseroth A, et al. Cancer Gene Ther. 2013 Feb;20(2):65-9. doi: 10.1038/cgt.2012.87. Epub 2012 Dec 14. Cancer Gene Ther. 2013. PMID: 23238593 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

322 results

Search Page

Filters